Eli Lilly (LLY) earnings Q3 2025
Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro. Shares of the company rose more than 2% in morning trading on Thursday. The pharmaceutical giant now expects its…
